Objective: To compare the efficacy and safety of rivastigmine (3 to 6 mg/day) vs placebo over 12 weeks in patients with traumatic brain injury and persistent cognitive impairment. Methods: This prospective, randomized, doubleblind, placebo-controlled study was conducted in 157 patients at least 12 months after injury. The primary efficacy measures were the Cambridge Neuropsychological Test Automated Battery (CANTAB) Rapid Visual Information Processing (RVIP) A= subtest and the Hopkins Verbal Learning Test (HVLT). The primary efficacy outcome was the proportion of patients who demonstrated 1.0 SD or greater improvement from baseline at week 12 on CANTAB RVIP A= or HVLT. Results: The percentage of responders at week 12 on either the CANTAB RVIP A= or HVLT was 48.7% for rivastigmine and 49.3% for placebo (p ϭ 0.940). Furthermore, for the overall study population, there were no significant differences for any of the secondary efficacy variables. In a subgroup of patients with moderate to severe memory impairment (n ϭ 81), defined as 25% impairment or greater on HVLT at baseline, rivastigmine was significantly better than placebo for a number of measures, including the proportion of HVLT responders and CANTAB RVIP mean latency. Conclusions: Rivastigmine was safe and well tolerated in patients with traumatic brain injury with cognitive deficits. Rivastigmine shows promising results in the subgroup of patients with traumatic brain injury with moderate to severe memory deficits.
NEUROLOGY 2006;67: [748] [749] [750] [751] [752] [753] [754] [755] Traumatic brain injury (TBI) has an incidence of 1,500,000 persons per year in the United States. More than 5 million people in the United States are living currently with a disability related to TBI 1 that significantly affects their lives and their families. Post-traumatic cholinergic deficits are common and contribute to the development of post-traumatic cognitive impairments. 2 Consequently, it is hypothesized that use of cholinesterase inhibitors (ChEIs) may improve cholinergic function pharmacologically. These agents are known to increase cholinergic function and to improve measures of cognition, behavior, and global function in patients with Alzheimer disease (AD) 3, 4 and may be beneficial in the treatment of cognitive deficits in patients with TBI. 2, 5, 6 Both acetylcholinesterase and butyrylcholinesterase (BuChE) play important roles in cholinergic transmission, and rivastigmine, which is approved for the treatment of mild to moderate dementia of the Alzheimer type, blocks both cholinesterases, although the clinical significance of BuChE inhibition has not been firmly established. [7] [8] [9] A preclinical study with rivastigmine supports the idea that this agent is potentially beneficial in TBI.
Rivastigmine administered 2 hours after closed head injury reduced edema and accelerated recovery from the neurologic deficits induced in a head injury model in mice. 10 Therefore, both clinical data in AD patients and preclinical data from TBI animal models suggest that rivastigmine may have efficacy in patients with TBI. The objective of this clinical study was to compare the efficacy and safety of rivastigmine (3 to 6 mg/day) with placebo over a treatment period of 12 weeks in patients at least 1 year after TBI who have persistent cognitive impairment.
Methods. Study design. We conducted a 12-week, prospective, randomized, double-blind, placebo-controlled study in 19 centers in the United States. Informed consent was obtained from patients, and the study was approved by an institutional review board/independent ethics committee and conducted in accordance with the Declaration of Helsinki and codes of Good Clinical Practice.
Eligible patients were randomly assigned in a 1:1 ratio to receive rivastigmine 3 to 6 mg/day or matching placebo. Randomization was performed using a validated system.
All patients started treatment with rivastigmine 1.5 mg BID or matching placebo, administered with food. After a minimum of 4 weeks at the starting dose, the dose of study medication may have been increased to 3.0 mg BID. If a patient experienced adverse events at 3.0 mg BID, the dose could be decreased to either 1.5 mg BID or 3.0 mg with breakfast and 1.5 mg with dinner (4.5 mg/ day). The goal was for patients to achieve their highest tolerated dose of rivastigmine, but not to exceed 6 mg/day. Patients had to be able to tolerate a minimum dose of rivastigmine (1.5 mg BID) to remain in the trial. Patients documented compliance with the medication regimen using a dosing diary.
Patients. Inclusion criteria. Eligible patients were men and women aged 18 to 50 years. Women were without childbearing potential or were practicing an acceptable method of birth control specified in the protocol. (Women were required to have a negative serum pregnancy test result immediately before study entry.) All patients satisfied the International Classification of Diseases, Ninth Revision, Clinical Modification 854.0 head injury criteria (nonpenetrating) and met or exceeded the American Congress of Rehabilitation Medicine criteria for mild TBI. 11 13 Results of neuropsychological tests were reviewed by a central reader to confirm patient eligibility. Current cognitive deficits were required to be present from the time of the injury, persistent, and deemed to be the result of the brain injury, which occurred at least 12 months earlier.
Exclusion criteria. Patients were excluded from the study if they currently had any of the following conditions: a medical, psychiatric, or substance use disorder that could significantly interfere with the assessment of their clinical or mental status or put them at special risk; acute, severe, or unstable pulmonary conditions; unstable cardiovascular disease; any primary neurodegenerative disorder (e.g., AD); epilepsy or seizure disorder; use of concurrent medications known to affect cognitive functioning in the TBI population; or clinically significant laboratory abnormalities in serum B 12 , folate, or thyroid function at screening. Patients were also excluded if they had experienced a myocardial infarction or active peptic ulcer within the last 3 months, a large intraparenchymal hemorrhage as evidenced by MRI, a history of major brain surgery (e.g., decompressive lobectomy, tumor resection), a penetrating brain injury, or a history of cerebrovascular disease or multiple sclerosis.
Concomitant medications.
Patients were permitted to continue with the following medications if the dose remained constant during the trial: vitamin E, estrogens, nootropics (e.g., piracetam, acetyl carnitine, ergoloid, ginkgo biloba), and psychotropic medications (e.g., antipsychotics, antidepressants, anxiolytics, sedatives, lithium). The use of trimethobenzamide was permitted for treating nausea and vomiting (a single oral dose of 250 mg on a PRN basis, with a maximum daily dose of 750 mg). Patients who experienced severe agitation, anxiety, or psychosis requiring therapeutic intervention could receive chloral hydrate (500-mg oral dose), repeated up to a maximum of 3 times in a 24-hour period; or quetiapine (25 mg every 8 hours), repeated up to a maximum of 3 times in a 24-hour period. These medications were not to be administered within 48 hours of cognitive testing.
Patients who deviated slightly from these criteria were considered for inclusion on a case-by-case basis. In these instances, the Investigator was required to contact the Medical Monitor and obtain approval before such patients could be randomized.
Assessments. The primary efficacy measures were the HVLT and the CANTAB RVIP A= subtest, which were administered at weeks 4, 8, and 12. The HVLT is a brief, orally administered measure that assesses verbal learning, verbal memory, long-term recall, and recognition memory. Alternate versions of the HVLT were administered at the different time points. The test consists of 12 words (4 words in each of 3 semantic clusters) which are read aloud (with a 1-second interval between each word) for three consecutive trials, each trial followed by a free-recall test. The derived variable (HVLT total Trials 1 through 3) is the total words recalled over the three trials (summed). After a 20-minute delay period, each subject is again required to recall as many of the 12 words as possible. The derived variable for this trial, HVLT delayed recall, is the number of words correctly recalled (0 to 12). From this delayed recall score, a savings score is calculated, with the delayed recall score divided by performance on the final learning trial (Trial 3). Finally, the patient is presented with a sheet containing 24 words (12 target words from the original list, 6 semantically similar words, and 6 novel, unrelated words) and is asked to mark which words appeared in the original list only. From this recognition memory trial, the HVLT-recognition discrimination index is derived from the scores for correct identification of target words and correct rejection of nontarget words. The CANTAB battery of tests is administered using a computer outfitted with a touch-screen monitor and assesses a variety of cognitive functions, including learning, memory, attention, and problem solving, as well as tests of executive function and vigilance. The RVIP A= subtest of the CANTAB is a signal detection measure of sensitivity to the target stimulus, and mean latency is the mean time taken to respond to target stimuli. The primary endpoint was the proportion of patients who demonstrated at least a 1 SD improvement from baseline on either the HVLT total Trials 1 through 3 (Ն4 word improvement) or the CANTAB RVIP A= subtest (Ն0.04 improvement) at week 12.
Secondary endpoints were change from baseline at week 12 in the following tests: 1) the CANTAB RVIP, Spatial Working Memory, Paired Associates Learning, and Reaction Time subtests (assessing cognition, attention, and executive function); 2) the HVLT (assessing verbal memory and recall); 3) the Controlled Oral Word Association 14 test (assessing verbal fluency and word-finding ability); 4) the WAIS-III Digit span (assessing short-term auditory and verbal memory); 5) the WAIS-III Letter Number Sequencing (assessing working memory, verbal memory and sequencing); 6) the Trail Making tests 15 Parts A and B (assessing sequencing, mental flexibility and divided attention); 7) the Neurobehavioral Functioning Inventory 16 (NFI) (assessing behavior in the following domains: depression, somatic, memory/attention, communication, aggression, and motor); 8) the Beck Depression Inventory II 17, 18 (assessing depression); and 9) the Diener Satisfaction with Life Scale 19 (assessing quality of life). The mean rating of change from baseline on the Clinical Global Impression of Change 20 (assessing overall functioning) was also a secondary measure. The same rater was to have administered the efficacy assessments to the same patient over the study period, and raters were blinded to the patient's treatment allocation.
Safety and tolerability were monitored throughout the trial. A complete laboratory evaluation, physical examination (including vital signs), neurologic examination, and 12-lead EKG were performed at baseline, at week 12, or at early termination. Safety was assessed at each visit through the collection of vital signs and information pertaining to adverse events and concomitant medications.
Statistical methods. The safety population included all patients who took at least one dose of study medication. Efficacy analyses were conducted in the intent-to-treat (ITT) population, which includes all patients who took at least one dose of study medication and from whom a baseline and at least one postbaseline measurement were obtained. Missing values for the efficacy ITT population were imputed using the last-observation-carriedforward technique. In addition, to be included in the primary efficacy analysis, patients were required not to miss a dose of study medication during the 3 days before the assessment.
Change from baseline was compared between treatment groups using an analysis of covariance model, which includes treatment and center as fixed effects and the baseline score as the covariate. All statistical tests were conducted against a two-sided alternative hypothesis, using a significance level of 0.05.
A sample size of 150 patients (75 for each treatment group) would achieve 80% power if the response rate of the rivastigminetreated group was at least 42%, assuming the response rate of the placebo group was 20% and using a two-sided 2 test with a significance level (␣) of 0.05.
Because of the study being an initial investigation for this indication, additional analyses were planned to identify subgroups more likely to benefit from treatment.
Results.
The study population consisted of 157 patients, 106 men and 51 women, with a mean (Ϯ SD) age of 37.1 Ϯ 10.5 years and a mean level of education of 14.1 Ϯ 2.6 years. There were no significant differences in the demographic characteristics between the rivastigmine-and placebo-treated groups (table 1). One hundred thirty-five patients (86%) had a known loss of consciousness (mean duration 22.9 Ϯ 28.3 days) associated with the TBI; however, these data were obtained from interviews and not verified by medical records. Duration of loss of consciousness using the patient's self-report is likely an overestimate because it may have also included a period of post-traumatic amnesia. A Glasgow Coma Scale (GCS) score collected within 24 hours of the injury (mean score, 6.5 Ϯ 3.5) was available for 76 patients (48%). Furthermore, 133 patients (85%) reported a loss of memory, 145 (92%) experienced an alteration in their mental state, and 101 (64.3%) exhibited neurologic deficits. There was a trend for the time since TBI to be longer in the placebotreated patients than the rivastigmine-treated patients (median 81.7 months vs 50.6 months; p ϭ 0.074). Ten patients in each treatment group had been previously treated with ChEIs, with 4 patients in each treatment group reported as having shown a response to the ChEI. Finally, 2 patients in each treatment group had experienced side effects associated with the previous ChEI treatment.
All patients were reported as having at least one past or coexistent medical condition, with more than half of the patients in each treatment group having at least one nervous system or psychiatric disorder, surgical or medical procedure, or injury, poisoning, and procedural complication. The most common coexistent medical conditions present at time of randomization were depression (33.8% for rivastigmine vs 44.2% for placebo), headache (26.3% vs 29.9%), insomnia (11.3% vs 22.1%), and dysarthria (17.5% vs 20.8%). Most of the patients were given at least one concomitant medication or significant nondrug therapy before the study, 69 patients (86.3%) and 67 patients (87.0%) in the rivastigmine-and placebo-treated groups, respectively. Overall, 70 patients (87.5%) and 64 patients (83.1%) completed the study in the rivastigmine-and placebotreated groups, respectively (figure 1). The most frequent reasons for discontinuation were adverse events (5 [6.3%] in the rivastigmine group and 7 [9.1%] in the placebo group), withdrawal of consent (2 [2.5%] in the rivastigmine group and 4 [5. 2%] in the placebo group), and lost to follow-up (1 [1.3%] in the rivastigmine-treated and 2 [2.6%] in the placebo group). Two patients (2.5%) in the rivastigmine group were discontinued because of protocol violation.
There was no difference in the duration of treatment for either group (mean of 81.0 Ϯ 23.0 days and 79.6 Ϯ 22.7 days for rivastigmine vs placebo, respectively; p ϭ 0.712). The mean last prescribed dose for all patients in the rivastigmine group was 5.38 mg/day.
Efficacy. The primary efficacy variable was the percentage of patients who improved on tests of attention or verbal memory, as defined by at least 1 SD improvement from baseline on either CANTAB RVIP A= or HVLT total Trials 1 through 3 for each treatment group. The primary analysis time point was week 12. Results from each time point (weeks 4, 8, and 12) are shown in table 2. There were no significant differences between rivastigmine and placebo in the percentage of responders, using this very conservative criterion for improvement, at any time point.
Secondary efficacy outcome measures included the change from baseline at week 12 for the various neuropsychological tests administered to the patients and are shown in table 3. Overall, for the entire study population, there were no significant differences between the rivastigmine-and placebo-treated groups. However, the results of the CANTAB RVIP A= at baseline suggest that the level of impairment in attention on this index was minimal.
For memory, however, the mean HVLT total Trials 1 through 3 at baseline suggest an impaired subpopulation in this particular cognitive domain. To further understand these results, an analysis was performed in the subgroup of patients with a greater degree of memory impairment, as defined by impairment of at least 25% on the HVLT at baseline.
The patients' expected HVLT scores were estimated from their premorbid IQs as assessed by the WAIS-III. 12 The percent impairment was determined using the baseline HVLT score minus the expected HVLT score, divided by the expected HVLT score for that patient. A patient was considered impaired if his or her baseline HVLT (total Trials 1 through 3) was at least 25% lower than the intelligence-adjusted expected score, as assessed by the WAIS-III Information and Vocabulary subtests. This criterion was adopted to have a constant level of discrepancy across all levels of baseline impairment, which would not occur if impairment was defined in terms of SD decrements. For instance, if Patient 1 had an expected score at the 50th percentile, a score 1 SD lower would be 17% worse than expected, whereas Patient 2 who had an expected score 1 SD below Patient 1 and whose score was 1 SD lower would have a 20% discrepancy.
Eighty-nine patients (n ϭ 45 and 44 for rivastigmine and placebo, respectively) had meaningful impairment (Ն25%) in memory according to this criterion. In this subgroup, there were no significant differences between the two treatment groups in demographic characteristics: age, sex, race, or duration of loss of consciousness, time since injury, and WAIS-III scores. At baseline, the mean HVLT score for this subgroup was 17.2, which was 11.19 points (or 2.8 SDs) below the expected normal score. The effect of treatment with rivastigmine in patients with 25% impairment or greater in memory was analyzed for all efficacy measures (rivastigmine: 42 patients; pla-cebo: 40 patients). Favorable trends in the rivastigmine group were observed in the percentage of responders on HVLT total Trials 1 through 3, where responder is defined as recalling at least 4 more words compared with baseline ( figure 2 ). An analysis of responders who demonstrated at least a 5-word improvement revealed a significantly higher rate of responders in the rivastigmine group at week 12 (figure 3). A significant difference in favor of rivastigmine was also observed in the change from baseline in CANTAB RVIP mean latency as early as 4 weeks after treatment ( figure 4) . Although not significant, positive trends were associated with rivastigmine treatment in the change from baseline for all other efficacy variables except the NFI and the CANTAB RVIP A=. For the NFI, the treatment differences were minimal, and there were no differences between treatment groups on the CANTAB RVIP A=. Safety and tolerability. The numbers of patients reporting at least one treatment-emergent adverse event were 57 (71.3%) and 53 (68.8%) for the rivastigmine-and placebo-treated groups, respectively. These adverse events were generally mild (rivastigmine: 34 [42.5%]; placebo: 33 [42.9%]) or moderate (rivastigmine: 22 [27.5%]; placebo: 19 [24.7%]) in severity. Only one patient in each treatment group experienced at least one severe adverse event. In the rivastigmine group, 1 patient reported severe noncardiac chest pain, and in the placebo group, 1 patient reported severe aggression, anger, and irritability. The most common adverse events were nausea, upper respiratory tract infection (which includes upper respiratory tract infec-tions, cold, and cold symptoms), headache, dizziness, and vomiting, each of which were reported in at least 10% of patients in the rivastigmine group (table 4) .
The most common adverse effects that resulted in discontinuation were gastrointestinal disorders (rivastigmine: 4 [5.0%]; placebo: 2 [2.6%]) and nervous system disorders (rivastigmine: 0; placebo: 4 [5.2%]). No deaths occurred during the study. The only serious adverse event report was an episode of substernal, noncardiac chest pain that occurred in the rivastigmine treatment group. The investigator did not consider the event to be related to study medication.
Treatment with rivastigmine was not associated with any clinically significant changes in vital signs or laboratory parameters. Furthermore, there were no significant differences between rivastigmine and placebo in changes from baseline in EKG parameters such as PQ/PR interval, QRS duration, or QT and QTc intervals.
Discussion. This study is the first large, multicenter, randomized, placebo-controlled pharmacologic trial in the United States for patients with persistent cognitive impairments after traumatic brain injury. The patients in this study were representative of the overall population of individuals with TBI with respect to age and sex. 21 The range of highest GCS scores available in the first 24 hours was 3 to 15 (average 5.5 to 6), suggesting that the group included patients with a broad range of initial injury severities. 21 Cognitive impairments and neuropsychiatric problems were chronic in this group of patients, having persisted at least 1 year and an average of 6 years after injury. The patients had comorbid conditions, including depression, and were often treated with other medications, generally maintained at a stable dose for the duration of the study. Concomitant medications that might directly interfere with cholinergic mechanisms were excluded, but other medications were allowed in order to maintain a representative group of patients with TBI who were taking multiple medications.
In this population of patients with TBI, rivastigmine was safe and well tolerated. The main side effects of rivastigmine in this group were nausea, headache, vomiting, and dizziness. The side effect profile for this younger population of patients with TBI was similar to that observed in the older population of patients treated for dementia. 3, 4 For inclusion into the study, patients were required to have impairments on cognitive tests of attention or memory obtained at screening that were at least 1 SD below expected values. With this inclusion criteria, both the rivastigmine-and placebotreated patients exhibited a similar extent of improvement after 12 weeks, and no differences were seen in the various cognitive measures. The response rate in the placebo-treated patients (49.3%) was much higher than the anticipated rate (20%), confirming the importance of using a placebo control, even in a population with persistent post-traumatic cognitive impairments.
When assessed using the CANTAB RVIP A=, patients in this study were not significantly impaired with attentional deficits. This measure may not have been sensitive to attentional deficits in this study population, and there may have been a "ceiling" effect that would not permit detection of significant improvement.
Because of the heterogeneity of this group with respect to performance on HVLT, an exploratory subgroup analysis was performed in patients who exhibited more severe memory impairment (Ն25% impairment). In this subgroup, there were significant treatment effects in the changes from baseline in CANTAB RVIP mean latency, and at least 5-point improvement on HVLT total Trials 1 through 3. Although not significant, positive trends in favor of rivastigmine were also seen on the majority of secondary outcome measures. Therefore, it seems from this post hoc analysis that rivastigmine was efficacious in those individuals with more severe impairments. This is an area where more research will be required to determine both the level of benefit experienced by these more impaired patients and whether this cutoff leads to replicable beneficial effects.
The cholinergic innervation of the cerebral cortex, arising from the nucleus basalis of Meynert, plays a major role in the regulation of attention and memory. 22, 23 Rivastigmine is believed to enhance cholinergic transmission through inhibition of acetylcholinesterase and butyrylcholinesterase. 9 The beneficial effect of rivastigmine may not become apparent unless there is significant enough depletion of limbic cholinergic activity causing a more profound impairment in memory or attention. The lack of effect of rivastigmine in patients with less severe memory impairment may indicate that the deficit is a result of some other pathophysiologic mechanism or a smaller cholinergic depletion that would be less responsive to cholinergic enhancement.
The only published study of the use of rivastigmine after TBI was an open study with subjective patient reports of response to drug treatment. 24 Patients received donepezil (n ϭ 27), galantamine (n ϭ 30), or rivastigmine (n ϭ 54). Of those using rivastigmine, 59% reported a "positive" response. In a randomized, placebo-controlled, double-blind study of patients with TBI, Zhang et al. 25 reported that donepezil was associated with improvements in performance on multiple cognitive measures. There are several important differences between this study and the current study. That study included 18 patients from two sites, and patients had an average GCS of 8 to 9 and were an average of 4 to 5 months postinjury. The measure of attentional deficits used in the study by Zhang et al., 25 the Paced Auditory Serial Addition Test, is more sensitive to deficits than the CANTAB RVIP A= that was used in the current study. In addition, the authors reported that the study excluded all patients with major psychiatric disorders, such as depression, and those treated with psychotropic medications. These individuals were included in the current study to provide a group of patients representative of the usual clinical TBI population.
Results from this study offer a greater understanding of TBI patient characteristics and may potentially help to better define the patient population to be studied in the future. TBI is a heterogeneous clinical condition, and the intent of the current study was to achieve a study population that was as representative as possible of individuals with persistent post-traumatic cognitive impairments in terms of heterogeneity of severity and inclusion of frequent comorbid conditions and medications. This heterogeneity, however, may have introduced sufficient variability to obscure a therapeutic effect of rivastigmine. Another limitation of the study is that correction for multiple comparisons were not performed so that it is possible that, using a p Ͻ 0.05 level, some of the significant differences could have occurred by chance; however, the various tests used were consistent with the a priori hypotheses.
The post hoc subgroup analysis suggests that treatment with rivastigmine had a significant im-provement in several efficacy measures when compared with placebo, but only in those patients with at least 25% impairment on the HVLT at baseline. Further studies in patients with TBI are needed to better define the patient population, which may achieve the best response with rivastigmine.
It is possible that the improvement observed in various cognitive tests reflects a "medicationenhanced" practice effect. Nonetheless, cognitive improvements in patients with persistent impairments after TBI are an important treatment goal, whether the result of a direct medication effect on memory or an indirect influence on a practice effect. These results point out the need for placebo-controlled studies in patients with TBI-associated memory impairment. Further investigations are needed to confirm these preliminary findings and to better define the patient population that may achieve the best response with rivastigmine.
